Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Feinberg: IAVI Neutralizing Antibody Consortium |
| Strategy: | Protein & peptide vaccines |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Assays completed |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1, randomized, double-blind, placebo-controlled dosage escalation trial to evaluate the safety and immunogenicity of eOD-GT8 60mer vaccine, adjuvanted in HIV-uninfected, healthy adult volunteers
Description
CAVD 725 (IAVI G001) is a Phase 1, dose escalation, clinical trial to evaluate the safety and immunogenicity of an eOD-GT8 60mer vaccine.
Sign in to see full information about this study and to download study data.
Products
AS01B eOD-GT8 60mer DPBSIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.